Uncategorized
Ocata Therapeutics Provides Corporate Update for the Second Quarter of 2015
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today provided a corporate update for the second quarter of 2015. “During the quarter, we made significant progress across multiple aspects of our business, most notably towards the initiation of a Phase 2 study in dry AMD and a pivotal study in SMD,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “In addition, the completion of our financing ha
